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It is currently thought that the dementia of Alzheimer’s disease is due to the neurotoxicity
of the deposits or aggregates of amyloid-β (Aβ) in the extracellular space of the cerebral
cortex. This model has been widely criticized because there is a poor correlation between
deposits and dementia. Others have questionedwhether Aβ is truly neurotoxic.Yet, in spite
of these concerns, the search for therapeutic agents has been based on the development
of mouse models transfected with mutant genes associated in humans with early onset
Alzheimer’s disease. A major limitation of these models is that although they exhibit many
of the pathological and clinical manifestation of the human disease, the bulk of individuals
who develop the dementia of Alzheimer’s disease have none of these mutant genes.
Furthermore, nine clinical trials of drugs that were effective in transgenic mice failed to
show any beneﬁt in patients. Finally, a major unresolved issue with the Aβ model is that
sinceAβ is produced in everyone, why are deposits only seen in the elderly?This issuemust
be resolved if we are to understand the etiology of the disease and develop test systems
for both diagnosis and drug discovery. Published studies from my laboratory demonstrate
that in human cerebrospinal ﬂuid immunoreactive Aβ is only present as a complex with
two chaperones, ERp57 and calreticulin and is N -glycosylated. This complex formation is
catalyzed by the posttranslational protein processing system of the endoplasmic reticulum
(ER). Others have reported that in plaque Aβ is present only as the naked peptide.Together
these results suggest that both plaque and dementia are secondary to an age related
decline in the capacity of the ER to catalyze protein, posttranslational processing. Since the
synaptic membrane proteins necessary for a functioningmemory are also processed in the
ER, these ﬁndingswould suggest that the loss of cognition is due to a decline in the capacity
of the neuron to produce and maintain functioning synapses. Work from my laboratory
and from others further indicate that the components of the ER, posttranslational, protein
processing pathway do dramatically decline with age.These data suggest that this decline
may be found in all cells and could account not only for the dementia of Alzheimer’s disease,
but also for many of the other manifestations of the aging process.These observations also
suggest that declining ER function has a role in twowell-recognized phenomena associated
with aging: a loss of mitochondrial function and a decrease in myelin. Finally, based on this
paradigm I propose new cellular and animals models for high-throughput screening for drug
discovery.
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INTRODUCTION
It is currently thought that the dementia of Alzheimer’s disease is
due to the neurotoxicity of the deposits or aggregates of amyloid-β
(Aβ) in the extracellular space of the cerebral cortex. In support of
this model various familial forms of the disease are characterized
by the early deposition of plaque and the development of demen-
tia. In light of the similar pathology observed between the familial
forms and the sporadic disease, many workers have developed
transgenic mouse models in which the animals were transfected
withmutant forms of the amyloid precursor protein (APP) and/or
presenilins 1 and 2. The APP normally is cleaved to form two
growth factors, αsAPP and βsAPP while the presenilins are com-
ponents of the γ secretase which clips the Aβ from the membrane.
The αsAPP is ﬁfty times more active than βsAPP’s (Herzog et al.,
2004), but the latter is present at much higher concentrations in
the brain (De Strooper et al., 2010).
Yet, a major philosophical problem with this approach is that
the vast majority of the elderly with late onset disease do not have
these mutations. In fact in genome wide association studies the
most consistently observed genetic variants associated with the
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late onset disease are found in the apoE and clusterin genes. Fur-
thermore, another difference between the late onset and familial
forms is that in human studies Pottier et al. (2012) reported that
the mRNA for APP was not elevated in late onset Alzheimer’s
disease, but was signiﬁcantly higher in individuals with the
various forms of the familial disease and Down’s syndrome.
Although western blotting of APP would be more deﬁnitive, when
increases are seen in mRNAs they are commonly accepted as a
measure of the total protein content. Hence, these data might sug-
gest that one possible underlying biochemical defect seen in the
familial forms of the disease may result in part from elevated lev-
els of APP. Studies on the role of APP in cellular metabolism may
give a clue as to how such elevations might lead to the early onset
disease.
Knockout studies of APP have reported that this growth fac-
tor is necessary for normal neuronal development (Dawson et al.,
1999). Furthermore, studies by Nikolaev et al. (2009) have sug-
gested that APP may play an important role at one particular
stage in normal embryonic development. As the brain develops
the embryo accumulates an excess of neurons and axons. These
investigators reported that APP activates death receptor 6 which
leads to axon pruning and apoptosis of the excess neurons. These
datamight suggest that the loss of cognition seen early in the famil-
ial forms of the disease before there is overt neuropathology could
result from excessive axon pruning due to the high levels of APP;
while later in the progression of the disease the high levels of APP
could lead to increased neuronal apoptosis with the development
of overt neurohistopathology.
Of greater concern there have been nine phase III clinical trials
of agents that were effective in transgenic mice but failed to show
any efﬁcacy in patients with late onset disease (Table 1).
The probability of nine failures in nine trials for a presumed
association is 29 or 1 in 512 which gives a p = 0.0195.
Many have ascribed these failures to the initiation of therapy
only after the subjects have exhibited signiﬁcant cognitive decline.
This was not true in two of these trials: the GEM (Ginkgo Evalua-
tion of Memory) trial of Ginkgo biloba (DeKosky et al., 2008) and
the Women’s Health Initiative Trial of estrogen alone (Espeland
et al., 2004).
In the GEM trial of G. biloba the subjects were followed for
7 years (DeKosky et al., 2008). The investigators observed no dif-
ference in the incidence of dementia between the placebo and the
Ginkgo treated subjects even though this agent was effective in
transgenic mice (Figure 2; Stackman et al., 2003).
Similarly, in the estrogen only arm of the Women’s Health Ini-
tiative Trial the subjects were also followed for 7 years (Figure 3;
Espeland et al., 2004). After an initial improvement in cognitive
scores which was probably due to a training effect, there were
similar declines in the scores of the placebo and estrogen groups.
Furthermore, permanent damage to neurons, such as apoptosis
and tangle deposits, is thought to only occur late in the disease.
Hence, the late administration of effective agents should at least
slow the cognitive decline, if not reverse the disease process. In
fact in many of the transgenic mouse studies, elderly animals
showed cognitive improvement when given some of these agents
(Imbimbo et al., 2012).
In all of these trials only solanezumab gave even the faintest
hope of slowing this decline. But even this agent failed to meet
the primary end points, and the noted beneﬁt was only seen
after combining the results of subjects with early disease in the
two trials of the drug, suggesting that the effect may not have
been sufﬁciently robust to be of clinical signiﬁcance (Doody,
2012). The Food and Drug Administration (FDA) has refused
to accept these ﬁndings as part of a future New Drug Application
(NDA).
In spite of these failures the general thrust of drug development
continues to seek new agents which will decrease the production
of Aβ or enhance its clearance. These agents include new anti-
bodies, vaccines, and γ-secretase inhibitors. Also a number of
ﬁrms have developed inhibitors of the β-secretase (BACE1). This
enzyme cleaves APP at the site which yields the Aβ peptide and the
βsAPP (Figure 1). This would seem to be a somewhat hazardous
approach for the long term treatment of patients with cognitive
impairment, since knocking out BACE1 has been shown to lead to
Table 1 | Failed phase III trials of agents which were effective in transgenic mouse models.
Drug Mechanism Reference Animal reference
1 Abeta vaccine Clear abeta Holmes et al. (2008) Janus et al. (2000) and
Morgan et al. (2000)
2 Tarenﬂurbil γ-Secretase inhibitor Green et al. (2009) Kukar et al. (2007)
3 Semagacestat γ-Secretase inhibitor Schor (2011) Abramowski et al. (2008)
4 MK-677 IGF-1 secretagogue Sevigny et al. (2008) Carro et al. (2002)
5 Ginkgo biloba Antioxidant DeKosky et al. (2008) and
Vellas et al. (2012)
Stackman et al. (2003)
6 Estrogen Hormone replacement Espeland et al. (2004) Levin-Allerhand et al. (2002)
and Carroll et al. (2007)
7 Docosahexaenoic acid Omega-3 fatty acid Quinn et al. (2010) Calon et al. (2004)
8 Bapineuzumab Monoclonal antibody Scheltens et al. (2012) Imbimbo et al. (2012)
9 Solanezumab Monoclonal antibody Doody (2012) Imbimbo et al. (2012)
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FIGURE 1 | Amino acid sequence of APP.
signiﬁcant deﬁcits in brain function (Laird et al., 2005; Hu et al.,
2010; Rajapaksha et al., 2011). The most serious of these problems
is that these animals have been reported to develop a seizure
disorder associated with an increased density of surface Nax1.2
channels and increased intrinsic ﬁring of isolated neurons and in
hippocampal brain slices (Hu et al., 2010). In a short term phase
I trial in normal volunteers the Merck BACE1 inhibitor, showed
no adverse effects. But considering that these adverse effects may
require long term administration, since it may dependent upon
inducing the Nax1.2 channels, it may take months to observe this
toxicity. Furthermore decreasing the level of Aβ in the brain may
require higher doses than those used in the phase I trial. Hence,
at higher doses for longer treatment periods there could be an
increased risk for observing the toxic side effects.
The only agent which has actually shown any promise of
a viable treatment for Alzheimer’s disease is methylene blue
(Wischik, 2012). This drug has been used as a urinary tract
disinfectant and analgesic since the 1930s. Basic studies have
demonstrated that its administration can lead to the loss of tan-
gles, another pathological manifestation of Alzheimer’s disease.
Tangles result from cellular stress which leads to hyperphospho-
rylation of a neuronal, cytoskeletal protein, tau (P-tau). The P-tau
then aggregates to form tangles. In a small phase II trial patients
receiving 138 mg per day of the drug showed a markedly reduced
cognitive decline during a 1 year study period. Yet, those receiving
twice the dose showed a parallel decline to the placebo. A chem-
ical modiﬁcation of this agent is currently going into a phase III
clinical trial. It will be interesting to see whether they can replicate
their initial ﬁndings.
A NEW PARADIGM FOR THE ETIOLOGY OF THE DEMENTIA OF
ALZHEIMER’S DISEASE
In light of these failures it would seem reasonable to examine new
paradigms for the etiology of this dreaded condition. A number
of years ago we asked the question:
Since Aβ is produced in everyone why is plaque only seen in the
brains of the elderly?
We postulated that normally Aβ is bound to proteins which
keep it in solution and thereby prevent plaque formation. And
indeed this turned out to be the case! When we ran western blots
of fresh or fresh frozen cerebrospinal ﬂuid (CSF) on denaturing
gels, we observed that there was only a single Aβ-immunoreactive
band which was consistently found at around 62 kDa (Figure 4;
Erickson et al., 2005). And was associated with an endoplasmic
reticulum (ER) chaperone, ERp57.
Furthermore, on immunopuriﬁcation we were able to isolate
the complex with antibodies to either Aβ or ERp57 (Figure 5).
A large number of studies on the biochemistry of the ER,
posttranslational, protein processing pathway have reported that
ERp57 binds to nascent proteins at N-glycosylation sites in
association with another ER chaperone, calreticulin. In line with
these observations, when the CSF was run on a native gel, the
band moved to 118 kDa and was associated with both ERp57 and
calreticulin (Figure 6).
The fact that the Aβ and the two chaperones all shifted to this
higher molecular weight along with the immunopuriﬁcation data
strongly supports our claim that the Aβ band is not either of the
two sAPP’s which have similar molecular weights.
Finally, since the Aβ found in plaque is only present as the
naked peptide, one possibility is that the complex was originally
in the plaque but broke down when it was solubilized by the usual
treatment with either concentrated formic or triﬂuoroacetic acid.
This is not likely to be the case since treatment of CSF under these
same conditions had no effect on the complex (channels 3 and 4)
(Figure 7).
Chaotropic agents such as urea and guanidine isothio-
cyanate also had no effect on the complex (channel 5 and 6). In
fact the only procedure which did affect the complex was storage
overnight at 4◦C in a pH 9.0 buffer (channel 9). The other inter-
esting aspect of this study was that the complex bound to a bonate
column, a synthetic lectin, suggesting that the Aβ is glycosylated
(channel 8).
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FIGURE 2 |The effect of Ginkgo biloba on Cognitive Function in the GEMTrial (taken from DeKosky et al., 2008).
The binding of ERp57 to APP is not unique. Two plasmamem-
brane receptors, the vasopressin receptor (Aiyar et al., 1989) and
the 1,25 dihydroxy vitaminDplasmamembrane receptor (Nemere
et al., 2004; Nemere, 2005), have also been shown to have bound
ERp57. The latter receptor is present in the plasma membrane
of enterocytes and modulates Ca++ uptake from the intestines.
The ERp57 would appear to have a role in signal transduction
since knocking it down or inhibiting it with antibody to its ter-
minal carboxy end inhibited 1,25 dihydroxy vitamin D stimulated
Ca++ uptake (Nemere et al., 2004; Nemere, 2005). It should also
be noted that the title of the publication by Aiyar et al. (1989)
demonstrating the binding of ERp57 to the vasopressin receptor
is incorrect. When these workers originally cloned and sequenced
ERp57, they erroneously identiﬁed it as a phosphatidylinositol
speciﬁc phospholipase C (Bennett et al., 1988). We found that the
ERp57 puriﬁed from rat liver (Srivastava et al., 1991) and rERp57
generated using the authors’ plasmid had no phospholipase activ-
ity (Srivastava et al., 1993) and instead it is a thiol:protein disulﬁde
oxidoreductase: a family of enzymes that catalyzes both the oxida-
tion and reduction of protein sulfur groups and is usually referred
to as a Protein Disulﬁde Isomerase (PDI).
THE EFFECT OF AGE ON THE COMPONENTS OF THE ER,
POSTTRANSLATIONAL, PROTEIN PROCESSING PATHWAY
In light of these ﬁndings we hypothesized that the dementia seen
in late onset Alzheimer’s disease is due to a decline in the capacity
of the neurons to catalyze the ER, posttranslational, protein
processing of the synaptic membrane proteins that are necessary
for a functioningmemory (Erickson et al., 2005)! In support of this
hypothesis we found that ERp57 does decline with age (Figure 8;
Erickson et al., 2006).
Several other ER chaperones showed similar declines (Table 2).
Finally, data from other laboratories would suggest that there
is also a decline in the N-glycosylation pathway with age. Firstly,
there is a reduced content of N-glycosylated proteins in the tissues
of the elderly (Kousvelari et al., 1988). Yet, this decline could be due
to decreases in gene transcription. On the other hand, a number
of studies have suggested that it may also be due to changes in the
activity of the N-glycosylation pathway. This concept is based on
the effect of age on the content of dolichol in various tissues, a
necessary cofactor for N-glycosylation.
The initial step in the N-glycosylation pathway is the synthe-
sis of an oligosaccharide bound to dolichol phosphate (Yan and
Lennarz, 1999; Helenius and Aebi, 2002; Kelleher and Gilmore,
2006; Figure 9). Dolichol is a highmolecular weight terpine which
serves as a cofactor for the cytosolic synthesis of the oligosac-
charide. Once the complex is fully synthesized, it is transferred
to the lumen of the ER and attached to an ξ -amino group of
an asparagine by an oligosaccharide transferase (OST; Kelleher
and Gilmore, 2006). The addition of the individual sugars to the
carbohydrate complex is catalyzed by a family of speciﬁcmonosac-
charide transferases (MST; Yan and Lennarz, 1999; Helenius and
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FIGURE 3 |The effect of estrogen alone on Cognitive Function in theWomen’s Health Initiative (taken from Espeland et al., 2004).
Aebi, 2002; Kelleher and Gilmore, 2006). The ﬁrst sugars added
to the dolichol phosphate are a pair of N-acetylglucosamines, fol-
lowed by nine mannoses and three glucoses. A large number of
studies have shown that as animals age there is a 5–10-fold increase
in the cellular content of both dolichol and dolichol phosphate (for
example see Marino et al., 1998). Since there is no increase in the
synthesis of dolichol, this ﬁnding is consistent with a blockage of
the addition of the ﬁrst N-acetylglucosamine. And indeed it has
been reported that the activity of ALG7, the MST that adds the
ﬁrst N-acetylglucosamine to the dolichol phosphate, does decline
with age (Mota et al., 1994).
OUR STUDIES INDICATE THAT
1. The Aβ-chaperone complex is formed during the normal
processing of APP in the lumen of the ER.
2. If this complex is not produced, then the naked peptide is
secreted and precipitates on its release from the cell to form
plaque.
3. On western blotting of a native gel we found that the complex
contains two ER chaperones, ERp57 and calreticulin.
4. In the CSF Aβ is probably also N-glycosylated.
5. These data indicate that plaque formation is due to a decline in
the capacity of the ER to catalyze the posttranslational process-
ing of APP. It may also account for many other manifestations
of aging.
6. Forty percentage of the proteins synthesized in the cell undergo
this same posttranslational processing in the ER, including
all the synaptic membrane proteins that are necessary for a
functioning memory.
7. With age there is a decrease in the components of the ER,
protein, posttranslational processing pathway.
THE ROLE OF DECREASED ER, PROTEIN,
POSTTRANSLATIONAL PROCESSING IN THE DECLINE WITH
AGE IN MITOCHONDRIAL FUNCTION AND MYELIN CONTENT
There are numerous phenomena associated with the aging pro-
cess. Two of the most fundamental are the decline with age in
mitochondrial function and myelin content. One of the major
problems with the Aβ model is that it does not address what the
relationship of either of these two well-documented processes has
to do with plaque deposition. I feel that both of these processes
may be related to the decline in ER function.
THE ROLE OF THE LOSS OF ER FUNCTION IN THE DECLINE IN
MITOCHONDRIAL FUNCTION
It is well-known that as mitochondria age they acquire structural
defects (Batlevi and La Spada, 2011). The damaged mitochondria
are cleared from the cell by autophagy. Many of the proteins which
make up the autophagic vacuoles are processed in the ER and golgi
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FIGURE 4 |Western blots of human, CSF with antibodies to ERp57 and
Aβ.
(Militello and Colombo, 2011). Hence, with a decline in ER func-
tion there is also a decline in autophagy. Such declines have been
associated with the onset of some age related neurodegenerative
diseases (Pan et al., 2008).
Second, themitochondria are directly bound to the ER through
the mitochondrial associated membrane (MAM; Merkwirth and
Langer, 2008; Hayashi et al., 2009; Schon and Przedborski, 2011).
This structure serves three, major functions. The ﬁrst is to
transport critical phospholipids from the ER, where they are syn-
thesized, into the mitochondria where they serve vital roles in the
maintenance of the structure and function of the mitochondria.
Further, it regulates Ca++ homeostasis in the mitochondria and
thereby oxidative phosphorylation.
A ﬁnal role for the ER in maintaining mitochondrial structure
and function is the control of mitochondrial ﬁssion and fusion. As
defectivemitochondria are cleared by autophagy, they are replaced
through a process involving bothmitochondrial ﬁssion and fusion.
Recent studies have indicated that several proteins in the MAM
playmajor roles in both of these processes (Merkwirth and Langer,
2008; Friedman et al., 2011). In particular two critical proteins
which tether the ER to the mitochondrial outer membrane are
mitofusin 1 and 2 (mfn1 and 2; Merkwirth and Langer, 2008;
Figure 10). These transmembrane proteins are located in both
FIGURE 5 | Immunoopurification of the Aβ-ERp57 Complex from
Human CSF. Aβ and ERp57 were isolated by immunoprecipitation. The
samples were then puriﬁed by western blotting on sodium docecyl
sulfate-polylacrylamide gel electrophoresis. The bands were identiﬁed by
antibodies to ERp57 (A) and Aβ (B). (Taken from Erickson et al., 2005)
FIGURE 6 |Western blot of the Aβ–ERp57–calreticulin complex from
human CSF after separation on a native gel (taken from Erickson et al.,
2005).
the ER membrane and the outer membrane of the mitochondria.
Both mfn1 and 2 undergo posttranslational processing in the ER.
Hence, a decline in the capacity of the ER to catalyze their post-
translational processing would be expected to have a profound
effect on mitochondrial structure and function. Such declines in
ER function could compromise the ability of the cell to maintain
metabolically active mitochondria.
THE ROLE OF THE LOSS OF ER FUNCTION IN THE DECREASE IN MYELIN
WITH AGE
Finally, the myelin sheaths are the plasma membranes of oligo-
dendrocytes and Schwann cells (Figure 11). This structure is also
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FIGURE 7 | Immunoblot of Aβ in CSF after treatments to dissociate the
Aβ–ERp57 complex. Channel 1 – molecular weight markers; channel 2 –
untreated CSF; channel 3 – CSF treated with 70% formic acid; channel 4 –
CSF treated with 80% triﬂuoroacetic acid; channel 5 – CSF treated with
6 M guanidine isothiocyante; channel 6 – CSF treated with 6 M urea;
channel 7 – CSF proteins which did not bind to a boronate column; channel
8 – CSF proteins which bound to a boronate column; channel 9 – treatment
of the complex with glycine buffer, pH 9.0 (taken from Erickson et al., 2005).
processed in the ER. The observed decline seen with age in the
capacity of the ER to catalyze this processing could explain the loss
of white matter consistently seen in the elderly and the slowing of
thought processes as we age.
PROPOSED CELLULAR AND ANIMAL MODELS FOR DRUG
DISCOVERY
These ﬁndings would suggest that we should be seeking agents for
the treatment of Alzheimer’s disease that enhance the components
of the ER, posttranslational, protein processing pathway. Classi-
cally the usual procedure for such a search has been to construct
test systems in which the promoter region for the target protein
is linked to a reporter system, such as luciferase, a beta galactosi-
dase or a ﬂuorescent protein. Yet, we now know that non-coding
FIGURE 8 |The effect of age on the ERp57 content of rat, hepatic
microsomes (taken from Erickson et al., 2006).
regions of the DNA and histone modiﬁcations play major roles in
controlling both transcription and translation of proteins. Hence,
potentially the most fruitful approach for high-throughput drug
screening would be to develop cell models in which compact ﬂu-
orescent proteins, such as green ﬂuorescent protein (GFP), are
embedded in an exon of the otherwise intact target gene. This
should maximize the number of potential target sites for small
molecule, drug discovery.
Such transgenic models are created in embryonic or induced
pluripotent stem cells by homologous recombination using a
variety of site speciﬁc endonuclease systems. These models are
usually createdwith eithermouse or human embryonic or induced
Table 2 | Effect of age on the content of rat liver ER chaperones (taken from Erickson et al., 2006).
Chaperone Peak concentration Concentration @ 874 days Constitutive Show cyclic Cyclic variation
μg/mg protein μg/mg protein decline % variation % decline
BiP 80.0 48.5 39 Yes 50
Calnexin 57.4 40.5 29 No –
Calreticulin 7.6 4.8 8 No –
ERp55 34.8 13.1 51 Yes 73
ERp57 15.4 8.2 32 Yes 71
ERp72 141 100 30 No –
Total 336.2 215.1 37
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FIGURE 9 |The N -glycosylation pathway (Helenius and Aebi, 2002).
FIGURE 10 |The tethering of the ER to the mitochondria (taken from
Merkwirth and Langer, 2008).
pluripotent stem cells. In the case of the mouse lines it would also
be possible to clone the cells and create transgenic, adult animals.
This is an important step since it is necessary to demonstrate that
the insertion of the ﬂuorescent protein does not lead to an animal
with compromised metabolism. Usually the indicator system is
inserted in either the ﬁrst or last exon of the native protein. If
these turn out to produce metabolically compromised cells, then
it would be necessary to insert the indicator in an exon that does
not compromise metabolic function. The stem cells can then be
transformed into a variety of tissue types by incubating with the
appropriate growth factors. With the construction of the labeled
cell lines, they can be used to automatically screen large libraries
of compounds in microtiter plate readers.
Similarly intact animals models could be developed in which
the relevant proteins have been knocked down. It is necessary to
only knock them down because knockouts of the chaperones and
components of the N-glycosylation pathway are lethal mutants.
The possible approaches could include a lox-cre system in which
the speciﬁc tissue cell type, such as neuronal cells have a hap-
loid knock out of the critical gene. Alternatively, it is possible to
develop models with a global knock down of the target gene(s)
with synthetic, antisense oligonucleotides.
In an unrelated study of the toxicity of methoxychlor, we
observed that feeding this insecticide to rats for 3 weeks specif-
ically increased the levels of ERp57 in hepatic microsomes (ER)
(Figure 12).
CONCLUSION
1. Nine phase III clinical trials of agents that were effective in
transgenic mice were not effective in patients with late onset
dementia.
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FIGURE 11 | Schwann cell.
FIGURE 12 |The effect of feeding of methoxychlor for 3 weeks on the
hepatic level of ERp57 (data taken from Morrell et al., 2000).
2. The reason that plaque does not form in the young is
because Aβ is normally N-glycosylated and bound to two ER
chaperones, ERp57 and calreticulin, which keep it in solution.
3. These components decline with age.
4. These ﬁndings suggest that the dementia seen in late onset
Alzheimer’s disease is due to a decline in the ER, posttransla-
tional processing of the synaptic, membrane proteins that are
necessary for a functioning memory.
5. It also suggests that the loss of mitochondrial function and
whitematter in the elderly is due to this decline in ER function.
6. This paradigm suggests new cellular models for drug discov-
ery in which ﬂuorescent proteins are inserted into an exon of
the various components of the ER, posttranslational, protein
processing pathway.
7. Animal models could be constructed in which the critical
proteins are knocked down by standard procedures and then
candidate drugs are administered to test whether they improve
cognition.
IMPLICATIONS FOR FUTURE DRUG DISCOVERY TO TREAT
ALZHEIMER’S DISEASE AND OTHER DISEASES ASSOCIATED
WITH AGING
Finally, over the past two decades the pharmaceutical industry and
funding agencies and foundations have made and are continuing
to make massive investments in the search for disease modify-
ing treatments for Alzheimer’s disease and other diseases of the
elderly. Although these efforts have taken a variety of approaches,
the bulk have sought treatments based on the Aβ hypothesis that
seek to improve cognitive function by decreasing the brain con-
tent of Aβ. Considering the number of these agents currently in the
pipeline, it is clear that this approach will continue to dominate
drug development for the foreseeable future. Yet, since many of
these new agents are merely variations on earlier failed investiga-
tional drugs, there is a signiﬁcant probability that they too will not
prove to be efﬁcacious in phase III clinical trials.
In view of the long, lag period between the initial identiﬁcation
of new targets and the ﬁnal regulatory approval of agents devel-
oped on the basis of new paradigms, it would seem prudent at this
point to consider other models for drug discovery in case the cur-
rent batch of investigational drugs fail to fulﬁll their early promise.
At the present time there is little chance that this lag period can
be foreshortened by evaluating therapeutic efﬁcacy based on sur-
rogate measures, because changes in the levels of such measures
have not been demonstrated to correlate with clinical efﬁcacy. For
example, the two most widely accepted biomarkers in the CSF
of disease status are low levels of Aβ and high levels of P-tau.
Yet in the recent failed bapineuzumab trial, P-tau levels did
decline, but the patients still showed no clinical beneﬁt (Blennow
et al., 2012).
Many have cited the experience in the treatment of hyperten-
sion in which demonstrating that decreasing blood pressure was
sufﬁcient grounds for drug approval. But this surrogate measure
was based on clinical trial data that had shown that a decrease
in blood pressure led to a pronounced decrease in morbid events
(VeteransAdministrationCooperative StudyGrouponAntihyper-
tensiveAgents, 1967, 1970). In fact the decreasewas so pronounced
that in the present era of drug trials, a Data and Safety Monitor-
ing Board would certainly have ended the 1970 trial no later than
3 years instead of continuing it for the full 5 years laid out in
the original protocol. Until such robust surrogate measures have
been identiﬁed or some agent does appear to show efﬁcacy in
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phase III clinical trialswhich could thereby represent a template for
future drug development, the most conservative approach would
appear to be for industry to cast a wide net of potential targets
for drug development rather than focusing on a single, possible
culprit which has failed to lead to the development of effective
agents.
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